Fellowship · Indianapolis, IN
Sponsored by Indiana University School of Medicine
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
The New England journal of medicine · 2021 · 1,358 citations · Rajiv Agarwal
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
European heart journal · 2022 · 965 citations · Rajiv Agarwal
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
The New England journal of medicine · 2025 · 232 citations · Rajiv Agarwal
An atlas of healthy and injured cell states and niches in the human kidney.
Nature · 2023 · 622 citations · Michael Eadon, Pierre Dagher, Tarek Ashkar
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Circulation · 2024 · 292 citations · Rajiv Agarwal
Molecular mechanisms and therapeutic targets for diabetic kidney disease.
Kidney international · 2022 · 544 citations · Rajiv Agarwal
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.
Nature reviews. Nephrology · 2022 · 525 citations · Rajiv Agarwal
Chronic kidney disease.
Nature reviews. Disease primers · 2025 · 157 citations · Rajiv Agarwal